SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Hair loss can be treated by correcting glucose metabolism in hairfollicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
A breakthrough in hairfollicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hairfollicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hairfollicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Hairfollicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.